Needham initiated coverage of Establishment Labs (ESTA) with a Hold rating and no price target The company’s U.S. Motiva launch should serve as a “major growth driver” and a potential source of upside while its minimally invasive procedures may expand the breast implant market, the analyst tells investors in a research note. However, the firm says Establishment’s international business has been weak, and that it worries the trade war could weigh on its international growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Hold Rating on Establishment Labs: U.S. Growth Potential vs. International Challenges
- Establishment Labs: Strong Q1 Results and Promising U.S. Launch Reinforce Buy Rating
- Strong Q1 Results and Successful Motiva Launch Drive Buy Rating for Establishment Labs Holdings
- Strong Market Penetration and Growth Potential Drive Buy Rating for Establishment Labs Holdings
- Establishment Labs Holdings: Buy Rating Backed by Motiva’s Superior Safety Profile